Form D · Pharmaceuticals
LIGAND PHARMACEUTICALS INC
La Jolla, CA · CIK 0000886163
Offering snapshot reported Jan 25, 2016 · SEC filing
- Reported sold
- $85.4M Offering amount: $85.4M
- Investors reported
- 22 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Jan 8, 2016 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jan 25, 2016 | Initial | $85,438,488 | No comparison | 22 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06c
- Duration over one year
- No
- Business combination
- Yes
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-255885
Source: Form D, filed Jan 25, 2016. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Jason Aryeh | Director |
| Charles S. Berkman | Director |
| Todd Davis | Director |
| Matthew W. Foehr | Director |
| Melanie Herman | Director |
| John L. Higgins | Director, Executive |
| David M. Knott | Director |
| Matthew Korenberg | Director |
| John Kozarich | Director |
| John Lamattina | Director |
| Sunil Patel | Director |
| Stephen Sabba | Director |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:
11119 North Torrey Pines Road Suite 200
La Jolla, CA, 92037
La Jolla, CA, 92037